Taro Board Concludes That Sun Tender Offer is Financially Inadequate, is a 'Sham' Offer and Violates Israeli Law

Taro Board Concludes That Sun Tender Offer is Financially Inadequate, is a 'Sham' Offer and Violates Israeli Law

Urges Shareholders Not to Tender Their Shares

HAWTHORNE, N.Y., Jul 10, 2008 (PrimeNewswire via COMTEX) -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company") (Pink Sheets:TAROF) said today that its Board of Directors (with Drs. Barrie Levitt and Daniel Moros and Ms. Tal Levitt neither participating in the deliberations nor voting) has unanimously concluded that Sun's offer is financially inadequate and is a "sham" offer, because we believe Sun knows that it will not be accepted by the shareholders. Sun's tender offer price is far below both the current market price of Taro's shares and the price Sun paid to acquire other blocks of the Company's shares in recent privately negotiated transactions. In order to gain control of Taro without paying a fair price to the shareholders, Sun is now making a "low-ball" offer that we believe it knows will not succeed, solely for the purpose of exercising certain options pursuant to an option agreement the Levitt and Moros families entered into with Sun at the time the merger agreement was signed over a year ago. In addition the Board has been advised by counsel that the offer is in violation of the Israeli Companies Law - 1999.
Accordingly, the Board recommends that Taro shareholders reject Sun's offer and not tender any of their shares.
The Taro Board's position is set forth in a filing being made today with the Securities and Exchange Commission and in a letter being mailed to the Company's shareholders. The full text of the letter follows:
July 10, 2008
Dear Fellow Shareholders:
On June 30, 2008, Sun Pharmaceutical Industries Ltd., through its subsidiary, Alkaloida Chemical Company Exclusive Group Ltd. (collectively, "Sun"), commenced an unsolicited tender offer for all of the outstanding ordinary shares of Taro Pharmaceutical Industries Ltd. ("Taro" or the "Company") at a price of $7.75 per share in cash.
Your Board of Directors (with Drs. Barrie Levitt and Daniel Moros and Ms. Tal Levitt neither participating in the deliberations nor voting) has unanimously concluded that Sun's offer is financially inadequate and is a "sham" offer, because we believe Sun knows that it will not be accepted by the shareholders. Sun's tender offer price is far below both the current market price of Taro's shares and the price Sun paid to acquire other blocks of the Company's shares in recent privately negotiated transactions. In order to gain control of Taro without paying a fair price to the shareholders, Sun is now making a "low-ball" offer that we believe it knows will not succeed, solely for the purpose of exercising certain options pursuant to an option agreement the Levitt and Moros families entered into with Sun at the time the merger agreement was signed over a year ago. In addition the Board has been advised by counsel that the offer is in violation of the Israeli Companies Law - 1999.
Accordingly, the Board unanimously recommends that you reject Sun's offer and NOT tender any of your shares.


 Here are the reasons your Board is urging you NOT to tender your
 shares into Sun's offer:

 * It is absurdly low

 * It is unfair

 * It is financially inadequate

 * It is unilateral

 * It is coercive

 * It is illegal

 * It is not the best we can do

 * It is a "sham" offer because we believe Sun knows that it will not
   be accepted by the shareholders


Sun's tender offer follows on the heels of our recent decision to terminate the merger agreement we entered into over a year ago with Sun. As you may recall, that agreement provided for the acquisition of Taro by Sun in a transaction in which shareholders would receive $7.75 in cash for each of their shares and allowed either party to terminate after December 31, 2007 if the merger had not yet been completed.
Following the announcement of the merger agreement in May 2007, there was significant shareholder opposition to the proposed merger at $7.75 per share, as well as litigation by shareholders to block the merger. At the time of the shareholders meeting to approve the merger, scheduled to take place in July 2007, there was a real concern that public statements made by Taro shareholders, and the numerous court motions filed by shareholders (including a motion to temporarily enjoin the shareholders meeting, which was ultimately rejected), may have caused confusion among the shareholders.
On the eve of the shareholders meeting that was scheduled to take place in July 2007, Sun requested a postponement of the meeting and asked for additional time to communicate directly with certain shareholders that opposed the merger. At the same time, Sun agreed to increase its investment in the Company by partially exercising its warrants and buying an additional 3,000,000 ordinary shares for $18 million. Sun also agreed, at our request, to eliminate the non-solicitation provisions of the merger agreement so that we could determine whether a third party might be willing to propose a transaction on terms that our shareholders would find more acceptable. Ultimately, however, Sun's efforts to overcome the opposition to the merger were unsuccessful, and the shareholders meeting to vote on the merger was never held.
Earlier this year, Sun acquired, for a price of $10.25 per share, all shares held by one of the opponents of the merger, who held close to 10% of the Company's ordinary shares. Sun then proposed that we amend the merger agreement to provide for an increased price of $10.25 per share. However, by this time the Company's business prospects were much better than they had been at the time the merger agreement was signed in May 2007. Our Board of Directors (with Drs. Levitt and Moros and Ms. Levitt neither participating in the deliberations nor voting) unanimously concluded that this price was financially inadequate and did not reflect the dramatic operational and financial turnaround that the Company had achieved over the last year or its improved future prospects. At the same time, the Board unanimously agreed to terminate the merger agreement with Sun, because Sun was unwilling to offer a fair price to acquire the Company and the operating restrictions in the merger agreement were having an adverse effect on the Company's business operations and profitability.


 The Board has concluded the following about Sun's offer:

 * It is absurdly low: Sun's $7.75 tender price is substantially
   below the current market price of Taro's shares, and even further
   below Sun's proposed increased merger price of $10.25;

 * It is unfair: Sun's tender price is far below the prices Sun
   recently paid to purchase Taro shares from large minority
   shareholders in privately negotiated transactions;

 * It is financially inadequate: Before we acted to terminate the
   merger agreement, we determined that, based on a number of
   factors, including Taro's operational and financial turnaround,
   the future value that Taro expects to achieve from the changes
   made in its business model, the value in Taro's new product
   pipeline and the advice received from Taro's financial advisor,
   Merrill Lynch based on Taro's most recent projections at the time,
   Sun's proposed $10.25 increased price was inadequate from a
   financial point of view;

 * It is unilateral: Before we acted to terminate the merger
   agreement, Sun repeatedly rebuffed our attempts to engage in
   meaningful price negotiations with us or our financial advisors;

 * It is coercive in at least three respects:

   -- First, Sun's proposal to increase the merger price to $10.25
      was conditioned on our agreeing to eliminate certain additional
      voting requirements that protect minority shareholders, and
      that our Israeli counsel advised us were required by Israeli
      law in order to approve the merger;

   -- Second, Sun's offer is designed to stampede shareholders into
      tendering their shares, at a price below the current market
      price, so that they won't end up as minority shareholders in a
      Sun-controlled company, by not providing for a second-step
      transaction at a fair price in which Sun would acquire any
      shares not tendered and purchased in the tender offer; and

   -- Third, Sun admits that its offer is being made at $7.75 in
      order to force the Levitt and Moros families to sell their
      shares at this now unfair and "low-ball" price pursuant to an
      option agreement those families entered into with Sun at the
      time the merger agreement was signed over a year ago. This is
      nothing more than a blatant attempt to gain control of Taro
      without paying a fair price to the shareholders;

 * It is illegal: The Company has been advised by its Israeli counsel
   that Sun's offer is required to, but does not, comply with the
   "special tender offer" rules under Israeli law that provide
   important protections to minority shareholders and that,
   therefore, Sun's offer is illegal. We have also been advised by
   our Israeli counsel that the "trust" described in Sun's offer to
   purchase will NOT remedy the illegality of Sun's offer;

 * It is not the best we can do: Since we acted to terminate the
   merger agreement, the Company and its advisors have had
   preliminary discussions with, and received expressions of interest
   from, other parties potentially interested in entering into
   strategic transactions with the Company, including purchasing the
   entire Company or making an investment in the Company. While
   there can be no assurance that any of these discussions will
   result in a formal proposal or that if a formal proposal is made
   that it will be pursued and consummated, at least two potentially
   interested purchasers have expressed interest at a price level in
   excess of the highest price Sun has ever indicated a willingness
   to pay. Understandably, these expressions of interest were and are
   subject to due diligence and other conditions. We are not opposed
   to a sale of the Company, but, given the dramatic turnaround in
   our performance over the last year, we believe that superior and
   fair values are attainable. We will prudently consider all
   alternatives with a view towards acting in the best interests of
   all shareholders; and

 * It is a "sham" offer because we believe Sun knows that it will not
   be accepted by the shareholders: Sun's objective is very clear to
   us. They are unwilling to acquire the Company at a fair price
   through good faith negotiations with the Board and the Company's
   management. In order to gain control of Taro without paying a fair
   price to the shareholders, Sun is now making a "low-ball" offer
   that we believe it knows will not succeed, solely for the purpose
   of exercising certain options pursuant to an option agreement the
   Levitt and Moros families entered into with Sun at the time the
   merger agreement was signed over a year ago.


Enclosed with this letter is a copy of the Company's Schedule 14D-9, which sets forth in more detail the background and reasons for the Board's recommendation that shareholders reject Sun's offer. The Schedule 14D-9 also includes other additional information required to be disclosed by law. We urge you to read it carefully and in its entirety and not to tender your shares to Sun.
We will keep you apprised of future developments and we greatly appreciate your continued support and encouragement.
On behalf of the entire Board of Directors,
Sincerely,
Barrie Levitt, M.D.
Chairman of the Board
If you have any questions or would like additional copies of this letter or the Company's Schedule 14D-9, please call our information agent, Georgeson Inc. Bankers and Brokers please call (212) 440-9800. All others please call toll free (866) 324-8878.
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.
The Taro Pharmaceutical Industries Ltd. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4733

SAFE HARBOR STATEMENT
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements that do not describe historical facts and statements that refer or relate to events or circumstances that the Company "believes," or "expects" to happen, or similar language. Although Taro believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurance that its expectations will be attained. Taro believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Certain factors that could cause or contribute to such differences include risks detailed from time to time in the Company's SEC reports, including its Annual Reports on Form 20-F. Forward-looking statements speak only as of the date they are made. Taro undertakes no obligation to update, change or revise any forward-looking statements, whether as a result of new information, additional or subsequent developments or otherwise.
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: Taro Pharmaceutical Industries Ltd.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.